肥胖与转移性或去势抵抗性前列腺癌生存期延长相关,且独立于肌少症和肌肉脂肪变性
该回顾性研究纳入182例转移性或去势抵抗性前列腺癌患者,评估肌少症、肌肉脂肪变性与肥胖对总生存的影响。中位随访33.9个月,体重指数与死亡率降低相关(HR 0.93,p=0.02),内脏肥胖亦相关(HR 0.99,p=0.003),且独立于肌少症和肌肉脂肪变性。高体重指数且无肌少症/肌肉脂肪变性者生存显著更长。
要点
- 肥胖(BMI≥30 kg/m²)与转移性或去势抵抗性前列腺癌患者死亡率降低独立相关。
- 肌少症和肌肉脂肪变性未削弱肥胖对生存的有利关联。
- 常规临床评估应包括体重指数和腰围测量,CT形态学分析可识别预后不良者。
核心结论
- 高体重指数和内脏肥胖与转移性或去势抵抗性前列腺癌患者死亡率降低相关,且独立于肌少症和肌肉脂肪变性。
- 高体重指数且无肌少症/肌肉脂肪变性者生存显著长于高体重指数伴肌少症/肌肉脂肪变性者或正常体重指数者。
研究设计与样本
- 回顾性分析2012至2017年于Vanderbilt综合前列腺癌门诊就诊的转移性或去势抵抗性前列腺癌男性,共纳入182例。
- 通过腹部CT测量骨骼肌面积和骨骼肌放射密度分别判定肌少症和肌肉脂肪变性。
- 采用Kaplan-Meier曲线和log-rank检验评估体成分对生存的影响,多变量Cox比例风险模型调整年龄、Charlson合并症指数、种族和临床分期。
主要发现
- 182例中,肥胖者占37.4%,肌少症者占53.3%,肌肉脂肪变性者占59.3%。
- 中位随访33.9个月,体重指数与死亡率降低相关(HR 0.93,p=0.02),内脏肥胖亦相关(HR 0.99,p=0.003)。
- 高体重指数无肌少症/肌肉脂肪变性者生存显著长于高体重指数伴肌少症/肌肉脂肪变性者或正常体重指数者(F[3,91]=4.03,p=0.01)。
关键数值与推荐
- 肥胖定义为体重指数30 kg/m²或以上。
- 肌少症和肌肉脂肪变性分别由腹部骨骼肌面积和骨骼肌放射密度确定。
临床怎么用
- 常规临床检查应包括计算体重指数和测量腰围。
- CT影像的形态学分析可识别预后不良风险患者。
局限性
- 回顾性分析设计。
- 单中心研究,样本量182例。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Obesity (body mass index 30 kg/m2 or greater) is associated with better overall survival in metastatic prostate cancer. Conversely, low muscle mass (sarcopenia) and low muscle radiodensity (myosteatosis) are associated with worse overall survival in many cancers. This study seeks to evaluate the relationship of sarcopenia, myosteatosis and obesity with overall survival in men with metastatic or castrate-resistant prostate cancer. MATERIALS AND METHODS: Retrospective analysis of men with metastatic or castrate-resistant prostate cancer and computerized tomography of abdomen/pelvis presenting to the Vanderbilt Comprehensive Prostate Cancer Clinic from 2012 to 2017 was performed. Demographic, pathological and survival data were described, with sarcopenia and myosteatosis determined from abdominal skeletal muscle area and skeletal muscle radiodensity, respectively. Kaplan-Meier curves and log-rank tests estimated the effect of body composition on survival. Multivariable Cox proportional hazard models were performed adjusting for age, Charlson comorbidity index, race and clinical stage. ANOVA was used to compare obese and nonobese men with and without sarcopenia or myosteatosis. RESULTS: Of 182 men accrued, 37.4% were obese, 53.3% sarcopenic and 59.3% myosteatotic. Over a median followup of 33.9 months, body mass index was associated with reduced mortality (HR 0.93, p=0.02), as was visceral adiposity (HR 0.99, p=0.003). Men with high body mass index without sarcopenia/myosteatosis lived significantly longer than men with high body mass index with sarcopenia/myosteatosis or normal body mass index men (F[3,91]=4.03, p=0.01). CONCLUSIONS: Both high body mass index and visceral adiposity in metastatic or castrate-resistant prostate cancer are associated with reduced mortality, independent of sarcopenia and myosteatosis. Therefore, routine clinical workup should include calculation of body mass index and measurement of waist circumference. Morphometric analysis of computerized tomography imaging can identify patients at risk for poor prognosis.
引用
- Xu MC, Huelster HL, Hatcher JB, et al. Obesity is Associated with Longer Survival Independent of Sarcopenia and Myosteatosis in Metastatic and/or Castrate-Resistant Prostate Cancer. J Urol. 2020. PMID: 33080148. doi:10.1097/JU.0000000000001428
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。